Uterine cancer is both common and, in many cases, curable. Every year, more than 1,300 women with some form of gynecologic cancer come to Memorial Sloan Kettering for treatment, including nearly 300 women with uterine cancer.
Our multidisciplinary team of experts includes specialists in oncology, gynecology, radiology, urology, and surgery. Your doctors will use sophisticated imaging and laboratory tests, if appropriate, to confirm your diagnosis and identify the characteristics of the tumor — and will then work together to determine the best treatment approach for you.
Recent progress in the development of new tools and surgical techniques has transformed the treatment of uterine cancer, resulting in greater surgical precision and fewer complications. At Memorial Sloan Kettering, outcomes following surgery for uterine cancer that is diagnosed in advanced stages or is recurrent are among the best in the world.
For many women, we are able to perform minimally invasive operations that enable them to go home the same day or require a hospital stay of only one day. Minimally invasive operations offer such benefits as decreased pain, improved cosmetic results, and a relatively fast recovery. Our innovative approach to identifying and removing only the necessary lymph nodes during surgery is an option that many women with early-stage uterine cancer select.
For women whose cancers are more advanced and require additional treatments following surgery, our medical oncologists are investigating chemotherapy regimens that include novel drugs and drug combinations available only through clinical trials at Memorial Sloan Kettering.
In one such development, our team led the way in demonstrating the efficacy of a targeted anti-vascular therapy known as bevacizumab (Avastin) in recurrent endometrial cancer. This treatment regimen is now considered a standard treatment for recurrent endometrial cancer and is recommended by the National Comprehensive Cancer Network (NCCN) guidelines.
In many cases we also have options for the small percentage (15 percent) of women with uterine cancer who have not yet gone through menopause and who would like to consider becoming pregnant at some point. To guide these women as they make treatment decisions, our Fertility Preservation and Parenthood After Cancer Treatment program can provide options for taking steps to preserve fertility before undergoing treatment.
We offer a variety of treatment options to women with uterine cancer based on the type of cancer found and the stage of the disease. Learn more about how we diagnose and treat endometrial cancer: